Brief: Prelude Therapeutics Posts Cash And Cash Equivalents Of $246.3 Mln As Of June 30, 2022, Expected To Fund Operations Into Second Half Of 2024

Prelude Therapeutics Incorporated

09/08/2022 14:52

Aug 9 (Reuters) - Prelude Therapeutics Inc  PRLD.O :
    * PRELUDE THERAPEUTICS - CASH AND CASH EQUIVALENTS OF $246.3
MILLION AS OF JUNE 30, 2022, EXPECTED TO FUND OPERATIONS INTO
SECOND HALF OF 2024
    * FOR THREE MONTHS ENDED JUNE 30, 2022, NET LOSS WAS $27.4
MILLION, OR $0.58 PER SHARE OF COMMON STOCK, BASIC AND DILUTED
    * Q2 EARNINGS PER SHARE VIEW $-0.61 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXb3R2CH 
Further company coverage:  PRLD.O 

 ((reuters.briefs@thomsonreuters.com;))